Hebrew University Medical Center, Jerusalem, Israel.
Am J Hum Genet. 2010 Jan;86(1):93-7. doi: 10.1016/j.ajhg.2009.12.007. Epub 2009 Dec 31.
Patients with Joubert syndrome 2 (JBTS2) suffer from a neurological disease manifested by psychomotor retardation, hypotonia, ataxia, nystagmus, and oculomotor apraxia and variably associated with dysmorphism, as well as retinal and renal involvement. Brain MRI results show cerebellar vermis hypoplasia and additional anomalies of the fourth ventricle, corpus callosum, and occipital cortex. The disease has previously been mapped to the centromeric region of chromosome 11. Using homozygosity mapping in 13 patients from eight Ashkenazi Jewish families, we identified a homozygous mutation, R12L, in the TMEM216 gene, in all affected individuals. Thirty individuals heterozygous for the mutation were detected among 2766 anonymous Ashkenazi Jews, indicating a carrier rate of 1:92. Given the small size of the TMEM216 gene relative to other JBTS genes, its sequence analysis is warranted in all JBTS patients, especially those who suffer from associated anomalies.
Joubert 综合征 2 型(JBTS2)患者患有神经疾病,表现为精神运动发育迟缓、张力减退、共济失调、眼球震颤和运动性眼球震颤以及不同程度的畸形,以及视网膜和肾脏受累。脑部 MRI 结果显示小脑蚓部发育不良,第四脑室、胼胝体和枕叶皮质也存在其他异常。该疾病先前已定位到染色体 11 的着丝粒区域。在来自 8 个阿什肯纳兹犹太家庭的 13 名患者中使用纯合子作图,我们在所有受影响的个体中发现了 TMEM216 基因中的纯合突变 R12L。在 2766 名匿名阿什肯纳兹犹太人中检测到 30 名杂合突变个体,表明携带者率为 1:92。鉴于 TMEM216 基因相对于其他 JBTS 基因较小,因此应对所有 JBTS 患者,特别是那些伴有相关异常的患者进行 TMEM216 基因的序列分析。